Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

Yubao Wang; Kermit V. Speeg; William Kenneth Washburn; Glenn Halff

doi:10.3748/wjg.v16.i43.5518

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

Yubao Wang, Kermit V. Speeg, William Kenneth Washburn, Glenn Halff

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

Original language	English (US)
Pages (from-to)	5518-5522
Number of pages	5
Journal	World Journal of Gastroenterology
Volume	16
Issue number	43
DOIs	https://doi.org/10.3748/wjg.v16.i43.5518
State	Published - Nov 21 2010

Keywords

Hepatocellular carcinoma
Liver transplantation
Mammalian target of rapamycin inhibitor
Sirolimus
Sorafenib

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.3748/wjg.v16.i43.5518

Cite this

@article{7926cf82dc8448e6809a65a951ede2b4,

title = "Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report",

abstract = "A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.",

keywords = "Hepatocellular carcinoma, Liver transplantation, Mammalian target of rapamycin inhibitor, Sirolimus, Sorafenib",

author = "Yubao Wang and Speeg, {Kermit V.} and Washburn, {William Kenneth} and Glenn Halff",

year = "2010",

month = nov,

day = "21",

doi = "10.3748/wjg.v16.i43.5518",

language = "English (US)",

volume = "16",

pages = "5518--5522",

journal = "World Journal of Gastroenterology",

issn = "1007-9327",

publisher = "Baishideng Publishing Group Inc",

number = "43",

}

TY - JOUR

T1 - Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation

T2 - A case report

AU - Wang, Yubao

AU - Speeg, Kermit V.

AU - Washburn, William Kenneth

AU - Halff, Glenn

PY - 2010/11/21

Y1 - 2010/11/21

N2 - A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

AB - A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Mammalian target of rapamycin inhibitor

KW - Sirolimus

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=78649687544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649687544&partnerID=8YFLogxK

U2 - 10.3748/wjg.v16.i43.5518

DO - 10.3748/wjg.v16.i43.5518

M3 - Article

C2 - 21086573

AN - SCOPUS:78649687544

SN - 1007-9327

VL - 16

SP - 5518

EP - 5522

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

IS - 43

ER -

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this